NCT06739759 Ovarian Hyperstimulation Syndrome Prevention
| NCT ID | NCT06739759 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Aljazeera Hospital |
| Condition | Ovarian Hyper Stimulation Syndrome (OHSS) |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-11-17 |
| Primary Completion | 2025-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2024-11-17 with a primary completion date of 2025-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Ovarian hyperstimulation is a very hazardous complication of ICSI
Eligibility Criteria
Inclusion Criteria: * Women with PCOS coming for ICSI Exclusion Criteria: * Women who donnot have PCOS
Contact & Investigator
Mahmoud Alalfy, MD
STUDY CHAIR
Aljazeera Hospital
Frequently Asked Questions
Who can join the NCT06739759 clinical trial?
This trial is open to female participants only, aged 19 Years or older, up to 42 Years, studying Ovarian Hyper Stimulation Syndrome (OHSS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06739759 currently recruiting?
Yes, NCT06739759 is actively recruiting participants. Contact the research team at mahmoudalalfy@ymail.com for enrollment information.
Where is the NCT06739759 trial being conducted?
This trial is being conducted at Giza, Egypt, Giza, Egypt.
Who is sponsoring the NCT06739759 clinical trial?
NCT06739759 is sponsored by Aljazeera Hospital. The principal investigator is Mahmoud Alalfy, MD at Aljazeera Hospital. The trial plans to enroll 300 participants.